Compare Amgen, Inc. (AMGN) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Payoneer Global Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Amgen, Inc. is far larger — about 81.7× Payoneer Global Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| AMGN | PAYO | |
|---|---|---|
Market Cap | $196.12B | $2.40B |
Sector | Health | Technology |
52-Week High | $388.16 | $7.42 |
52-Week Low | $271.18 | $4.27 |
Enterprise Value | $241.41B | $2.14B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Payoneer Global (PAYO) trades at $7.10, up 0.14% with a $2.3B market cap, following Nuvei's $2.75B acquisition announcement. The stock shows bullish technical signals with strong moving averages, while fundamentals reveal solid revenue growth to $821M in 2025 and healthy gross margins of 79.4%. Recent earnings beat expectations in Q1 2026, though Q4 2025 missed. Analyst consensus is bullish with a $8.20 price target, but acquisition-related legal scrutiny creates uncertainty.
The acquisition by Nuvei at $7.40 per share provides a near-term floor, but potential undervaluation claims and regulatory approval pose risks. Long-term investors may see upside if the deal completes above current price, while volatility is expected during the process. Revenue stability and margin strength support fundamental value, but execution risks and competitive pressures remain key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
